United Arab Emirates - English - MOHAP (Ministry of Health & Prevention) - وزارة الصحة ووقاية المجتمع.الإمارات

alphamed drug store saudi arabia - 10's (0.5 ml x 10 single dose ampoules) - injection - 10 lf/0.5 ml - immunologicals , vaccines-vaccines , antisera

New Zealand - English - Medsafe (Medicines Safety Authority)

universal specialities ltd trading as usl medical - benzoyl peroxide 10.885%{relative} (includes 8.85% overage) - lotion - 10 % - active: benzoyl peroxide 10.885%{relative} (includes 8.85% overage) excipient: glyceryl monostearate isopropyl palmitate macrogol stearates palmitic acid propylene glycol stearic acid water zinc myristate

New Zealand - English - Medsafe (Medicines Safety Authority)

universal specialities ltd trading as usl medical - benzoyl peroxide 10%; sulfur 20% (precipitated) - lotion - 10%/20% - active: benzoyl peroxide 10% sulfur 20% (precipitated)

New Zealand - English - Medsafe (Medicines Safety Authority)

pacific pharmaceuticals limited (part of mylan) - benzoyl peroxide 10%{relative} (as hydrous) - topical gel - 10 % - active: benzoyl peroxide 10%{relative} (as hydrous) excipient: carbomer 940 colloidal silicon dioxide disodium edetate dihydrate docusate sodium poloxamer propylene glycol purified water

New Zealand - English - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - asparaginase 10000 [iu] (derived from cultures of e.coli hap ex japan, expressed as 10,000ku) - powder for injection - 10,000ku - active: asparaginase 10000 [iu] (derived from cultures of e.coli hap ex japan, expressed as 10,000ku) - treatment of acute lymphoblastic leukaemia

New Zealand - English - Medsafe (Medicines Safety Authority)

roche products (nz) ltd - urea 10% - topical cream - 10 % - active: urea 10%

New Zealand - English - Medsafe (Medicines Safety Authority)

reckitt benckiser (new zealand) limited - benzoyl peroxide 10.5%{relative} (added as hydrous benzoyl peroxide, 14%w/w) - lotion - 10 % - active: benzoyl peroxide 10.5%{relative} (added as hydrous benzoyl peroxide, 14%w/w) excipient: cetyl alcohol citric acid monohydrate colloidal silicon dioxide glyceryl 1-monostearate methyl hydroxybenzoate propyl hydroxybenzoate propylene glycol purified water sodium citrate dihydrate sodium laurilsulfate

New Zealand - English - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - influenza virus a/wellington/i/2004(h3n2)-like strain 10ug ([influenza virus a/wellington/i/2004 ivr-139(10 µg/ha)]);  ; influenza virus b/shanghai/361/2002-like strain 15ug ([b/jiangsu/10/2003 (15µg/ha)]);  ; influenza virus haemagglutinin type a/new caledonia/20/99 h1n1-like strain 15ug ([a/new caledonia/20/99 ivr-116 (15µg/ha)]);   - solution for injection - 10µg/15µg/15µg per dose - active: influenza virus a/wellington/i/2004(h3n2)-like strain 10ug ([influenza virus a/wellington/i/2004 ivr-139(10 µg/ha)])   influenza virus b/shanghai/361/2002-like strain 15ug ([b/jiangsu/10/2003 (15µg/ha)])   influenza virus haemagglutinin type a/new caledonia/20/99 h1n1-like strain 15ug ([a/new caledonia/20/99 ivr-116 (15µg/ha)])   excipient: dibasic sodium phosphate dihydrate monobasic potassium phosphate neomycin sodium chloride water for injection

Australia - English - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - rosuvastatin calcium, quantity: 10.42 mg - tablet, film coated - excipient ingredients: magnesium stearate; light magnesium oxide; lactose; crospovidone; microcrystalline cellulose; titanium dioxide; lactose monohydrate; hypromellose; triacetin; brilliant blue fcf aluminium lake; iron oxide red; quinoline yellow aluminium lake - cavstat 10 should be used as an adjunct to diet when the response to diet and exercise is inadequate. ,prevention of cardiovascular events cavstat 10 is indicated for prevention of major cardiovascular events in men ?50 years old and women ?60 years old with no clinically evident cardiovascular disease but with at least two conventional risk factors for cardiovascular disease (hypertension, low hdl-c, smoking, or a family history of premature coronary heart disease). cavstat 10 is indicated to:,? reduce the risk of nonfatal myocardial infarction ? reduce the risk of nonfatal stroke ? reduce the risk of coronary artery revascularisation procedures.,in patients with hypercholesterolaemia cavstat 10 is indicated for the treatment of hypercholesterolaemia (including familial hypercholesterolaemia). ,prior to initiating therapy with cavstat 10, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated.

Australia - English - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - rosuvastatin calcium, quantity: 10.42 mg - tablet, film coated - excipient ingredients: magnesium stearate; lactose; microcrystalline cellulose; crospovidone; light magnesium oxide; titanium dioxide; lactose monohydrate; hypromellose; triacetin; brilliant blue fcf aluminium lake; iron oxide red; quinoline yellow aluminium lake - cavstat 10 should be used as an adjunct to diet when the response to diet and exercise is inadequate. ,prevention of cardiovascular events cavstat 10 is indicated for prevention of major cardiovascular events in men ?50 years old and women ?60 years old with no clinically evident cardiovascular disease but with at least two conventional risk factors for cardiovascular disease (hypertension, low hdl-c, smoking, or a family history of premature coronary heart disease). cavstat 10 is indicated to:,? reduce the risk of nonfatal myocardial infarction ? reduce the risk of nonfatal stroke ? reduce the risk of coronary artery revascularisation procedures.,in patients with hypercholesterolaemia cavstat 10 is indicated for the treatment of hypercholesterolaemia (including familial hypercholesterolaemia). ,prior to initiating therapy with cavstat 10, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated.